EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

Palivizumab coverage rates among moderate-to-late preterm infants in Korea: a nationwide cross-sectional study

Seungyeon Kim, Saram Lee, Young June Choe, Ju Sun Heo

Epidemiology and Health · 2025

DOI: 10.4178/epih.e2025015 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Epidemiology and Health, 2025. Verfasst von Seungyeon Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Dankook University, cheonan, Korea. Hauptthemen laut MEDLINE: Palivizumab, Infant, Premature, Respiratory Syncytial Virus Infections, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University Hospital, Korea University Anam Hospital, Korea University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Since October 2016, Korea has implemented a national reimbursement program for palivizumab aimed at moderate-to-late preterm (MLPT) infants born between 32 0/7 weels and 35 6/7 weeks of gestation during the respiratory syncytial virus (RSV) season (October–March). However, large-scale data on coverage rates and associated factors remain limited. This study evaluated palivizumab coverage rates and identified predictive factors influencing its administration in MLPT infants.METHODS: This nationwide, population-based cross-sectional study utilized data from the Korean National Health Insurance Service collected between October 2016 and March 2019. MLPT infants eligible for palivizumab reimbursement were divided into administration and non-administration groups. Seasonal and overall coverage rates were assessed. A multivariate logistic regression analysis examined factors associated with palivizumab administration, with a focus on infant and maternal characteristics.RESULTS: Among 2,843 eligible MLPT infants, 1,201 (42.2%) received palivizumab, while 1,642 (57.8%) did not. Although coverage rates increased annually, they remained suboptimal. Lower palivizumab prophylaxis coverage was observed in infants with higher gestational ages, female sex, absence of low birth weight, those born in March, residents of non-capital areas, infants not admitted to a neonatal intensive care unit at birth, and infants of mothers aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PalivizumabInfant, PrematureRespiratory Syncytial Virus InfectionsAntiviral AgentsHumansCross-Sectional StudiesRepublic of KoreaFemaleInfant, NewbornMale

Stichwörter der Autor:innen

PalivizumabPremature infantProphylaxisRespiratory syncytial virusRespiratory tract infectionsVaccination coverage

Substanzen

PalivizumabAntiviral Agents

Autor:innen und Institutionen

  • College of Pharmacy, Dankook University, cheonan, Korea.
  • Department of Transdisciplinary Medicine, Seoul National University Hospital, Seoul, Korea.
  • Department of Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • Innovative Medical Technology Research Institute, Seoul National University Hospital, Seoul, Korea.
  • Department of Pediatrics, Anam Hospital, Korea University College of Medicine, Seoul, Korea.
  • Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.

Förderung

  • Seoul National University Hospital
  • Korea University Anam Hospital
  • Korea University
  • National Research Foundation of Korea
  • Ministry of Science and ICT

Zitieren

APA

Kim, S., Lee, S., Choe, Y. J., & Heo, J. S. (2025). Palivizumab coverage rates among moderate-to-late preterm infants in Korea: a nationwide cross-sectional study. Epidemiology and Health. https://doi.org/10.4178/epih.e2025015

Vancouver

Kim S, Lee S, Choe YJ, Heo JS. Palivizumab coverage rates among moderate-to-late preterm infants in Korea: a nationwide cross-sectional study. Epidemiology and Health. 2025. doi:10.4178/epih.e2025015

BibTeX
@article{Kim2025,
  author = {Kim, Seungyeon and Lee, Saram and Choe, Young June and Heo, Ju Sun},
  title = {Palivizumab coverage rates among moderate-to-late preterm infants in Korea: a nationwide cross-sectional study},
  journal = {Epidemiology and Health},
  year = {2025},
  doi = {10.4178/epih.e2025015}
}
Kostenlos starten →